MD
Professor, Medicine-Oncology
Associate Director for Finance, UNC Lineberger Clinical Protocol Office
UNC-Chapel Hill
Clinical Research
Thoracic Oncology Program
Meet Jared Weiss
Area of Interest
My primary focus is on personalized immunotherapy for lung cancer and for head/neck cancer. At the current time, my primary effort is PANDA-VAC, a personalized and adaptive vaccine generated from prediction of Neo-antigens (LCCC1804). I am also in the early stages of cellular therapeutics work targeting GD2 and MAGE-A4 and in very early work on a novel mechanism for better selection of TIL (tumor infiltrating lymphocytes) products.
I am the national PI for investigator-initiated trials evaluating the introduction of oncolytic virus into malignant pleural effusions (LCCC1626), induction chemo-immunotherapy in locally advanced, surgically resectable head and neck cancer (LCCC1621), and adjuvant immune-radiotherapy in head/neck cancer (LCCC1725). A funded effort to evaluate LXR/ApoE agonism to reduce MDSCs (LCCC1925) is funded and in the protocol writing stage.
I also lead and participate in several international industry efforts; key amongst these is ILIAD (IM-202, ilixadencel dendritic cell infusion into solid tumors). Other efforts include immunolight, LOXO-292 (RET inhibitor) and trilacyclib (CDK4/6 inhibitor for myelopreservation in SCLC, manuscript under minor revisions at Annals of Oncology).
Awards and Honors
- Jimmy V Foundation Translational/Clinical Award, 2018-2020
- UNC Seq V2 award, 2018-2021
News and Stories
Expert advice for living with chronic cancer
UNC Health social worker Rose Wilson, MSW, and UNC Health oncologist Jared Weiss, MD, discuss the physical and emotional considerations of long-term cancer care.
Clinical trial improves man’s quality of life with tongue cancer
Vance Aldrich Bell III experienced positive life-changing results after participating in a clinical trial for squamous cell carcinoma of the tongue.